Research!America seeks $26 billion boost to NIH, CDC, FDA funding in FY21

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a letter to House and Senate leaders, Research!America has asked for a massive boost in federal spending to address the damage the U.S. research organizations have sustained as a result of the COVID-19 pandemic.

”Funding of $26 billion is the minimum needed to re-seed the U.S. R&D continuum across all federal research funding, and to address gaps in voluntary health organization and philanthropic research funding resulting from the pandemic,” Mary Woolley, president and CEO of Research!America, writes in the letter. “NIH Director Francis Collins has indicated that NIH alone needs $10 billion to address erosion in grant dollars.”

The text of the letter follows:

Dear Leader McConnell, Speaker Pelosi, Minority Leader Schumer, and Minority Leader McCarthy:

We greatly appreciate your continued bipartisan commitment to responding resolutely and responsibly to the COVID-19 pandemic. Among the extreme impacts of COVID-19 is the destabilizing and stultifying effect on progress against the plethora of other deadly and debilitating diseases that threaten Americans and populations across the globe. We are writing to urge you to coalesce around two actions to empower desperately needed, lifesaving progress.

First, we ask that you provide the funding needed to restart research stalled or reprogrammed as a result of the pandemic. NIH Director Francis Collins has indicated that NIH alone needs $10 billion to address erosion in grant dollars. Funding of $26 billion is the minimum needed to re-seed the U.S. R&D continuum across all federal research funding, and to address gaps in voluntary health organization and philanthropic research funding resulting from the pandemic.

Second, we ask that you craft Fiscal Year 2021 appropriations in a way that accommodates unanticipated, but critically important, pandemic and VA funding needs while continuing to advance other top American priorities. The current budget caps were established before COVID-19 altered virtually every facet of American life. The pandemic did not, however, alter the importance of such enduring priorities as meeting the needs of our nation’s veterans and speeding progress against cancer, Alzheimer’s, and other destructive health threats. We ask that you exempt funding for the VA MISSION Act and pandemic-related spending from the budget caps to enable robust growth in the annual budgets of NIH, CDC, FDA, AHRQ and other research agencies critical to medical and public health progress.

We appreciate your consideration of these two pivotally important actions. Thank you, and please express our gratitude to your respective staff members, for your exceptionally hard work on behalf of the American people.

Table of Contents

YOU MAY BE INTERESTED IN

In last week’s issue of The Cancer Letter, Jacquelyn Cobb, associate editor, wrote a story about the then-promising legislative package that was passed by the U.S. House of Representatives Jan. 22. At the time, the package was expected to pass in the Senate, provide funding for the federal government through fiscal year 2026, and prevent a government shutdown that looms Jan. 30. 
A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.
The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several  aggressive cuts the White House had proposed for NIH.
This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login